Apotex Health Corp., one of Canada’s largest pharmaceutical companies, is preparing to go public on the Toronto Stock Exchange with an offering that could raise up to C$1.2 billion. The company filed a preliminary prospectus on May 28, 2026, under the ticker APTX.
What the offering looks like
The IPO is structured as a mix of newly issued treasury shares and secondary shares. The secondary component comes primarily from SK Capital Partners, the controlling shareholder looking to monetize part of its stake.
Estimates for the offering size range between C$750 million and C$1 billion, with a potential upper ceiling of C$1.2 billion depending on demand.
Apotex’s financials give the listing some serious backing. The company reported C$3.5 billion in revenue alongside C$374 million in earnings.
